Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "ESOMEPRAZOLE SODIUM FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"ESOMEPRAZOLE SODIUM FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company") announces

that a digestive system medicine "Esomeprazole Sodium for Injection" (brand name: "Enxin" ( 恩信)) developed by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ( 江蘇正大豐海製藥有限公司), a

subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China.

Esomeprazole Sodium for Injection is the fourth generation proton pump inhibitor and the latest generation of clinically available antacid product, which has the characteristics of rapid, strong and long-lasting effects. This product has been included in many authoritative guidelines in China and abroad. It is a first-line drug for the treatment of acid-related diseases such as gastrointestinal ulcers and gastrointestinal bleeding, and is widely used in clinical departments such as gastroenterology, surgery, intensive care unit (ICU) and emergency department.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 27 November 2019

As at the date of this announcement, the Board comprises eight executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.